CA2565227A1 - Human complement c3 derivates with cobra venom factor-like function - Google Patents

Human complement c3 derivates with cobra venom factor-like function Download PDF

Info

Publication number
CA2565227A1
CA2565227A1 CA002565227A CA2565227A CA2565227A1 CA 2565227 A1 CA2565227 A1 CA 2565227A1 CA 002565227 A CA002565227 A CA 002565227A CA 2565227 A CA2565227 A CA 2565227A CA 2565227 A1 CA2565227 A1 CA 2565227A1
Authority
CA
Canada
Prior art keywords
protein
modified
cvf
complement
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002565227A
Other languages
English (en)
French (fr)
Inventor
Carl-Wilhelm Vogel
David C. Fritzinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Hawaii at Hilo
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2565227A1 publication Critical patent/CA2565227A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
CA002565227A 2004-04-30 2005-04-29 Human complement c3 derivates with cobra venom factor-like function Abandoned CA2565227A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US56706904P 2004-04-30 2004-04-30
US60/567,069 2004-04-30
US65324705P 2005-02-14 2005-02-14
US60/653,247 2005-02-14
US66735205P 2005-03-31 2005-03-31
US60/667,352 2005-03-31
PCT/US2005/015119 WO2005107785A2 (en) 2004-04-30 2005-04-29 Human complement c3 derivates with cobra venom factor-like function

Publications (1)

Publication Number Publication Date
CA2565227A1 true CA2565227A1 (en) 2005-11-17

Family

ID=35320733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002565227A Abandoned CA2565227A1 (en) 2004-04-30 2005-04-29 Human complement c3 derivates with cobra venom factor-like function

Country Status (9)

Country Link
US (2) US8632780B2 (enExample)
EP (1) EP1755658A4 (enExample)
JP (1) JP2008502323A (enExample)
KR (1) KR20070036057A (enExample)
AU (1) AU2005240096A1 (enExample)
CA (1) CA2565227A1 (enExample)
IL (1) IL178905A0 (enExample)
MX (1) MXPA06012321A (enExample)
WO (1) WO2005107785A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003159A1 (en) 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
US8632780B2 (en) 2004-04-30 2014-01-21 University Of Hawaii Human complement C3 derivates with cobra venom factor-like function
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
RU2549468C2 (ru) * 2013-08-09 2015-04-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН") Способ определения стабилизации с3-конвертазы классического пути активации комплемента человека
WO2015192101A1 (en) * 2014-06-12 2015-12-17 University Of Hawaii Uses of humanized cobra venom factor for reducing or preventing immunogenicity
US20190016766A1 (en) * 2015-10-07 2019-01-17 Daniel E. Benjamin Use of improved modulators of complement function as cancer therapeutics
US11903996B2 (en) * 2015-10-07 2024-02-20 David C. Fritzinger Modulators of complement function
CN106472354B (zh) * 2016-10-21 2019-05-31 新希望六和饲料股份有限公司 一种成年鸡用饲料盘
CN106472359B (zh) * 2016-10-21 2019-07-26 新希望六和饲料股份有限公司 一种1-3周龄雏鸡用饲料盘

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661347A (en) * 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
CA2160127A1 (en) * 1993-04-07 1994-10-13 David C. Fritzinger Dna encoding cobra c3, cvf1, and cvf2
US5714344A (en) * 1993-04-07 1998-02-03 Georgetown University Protease-derivatized CVF
WO1996007738A2 (en) * 1994-09-08 1996-03-14 Imutran Limited Modified human c3 proteins
US6221657B1 (en) * 1995-09-08 2001-04-24 Imutran Limited Modified human C3 DNA sequences and vectors
US5922320A (en) * 1996-06-14 1999-07-13 Georgetown University Recombinant proCVF
WO2005003159A1 (en) * 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
US8632780B2 (en) * 2004-04-30 2014-01-21 University Of Hawaii Human complement C3 derivates with cobra venom factor-like function
US20100179092A1 (en) * 2006-11-15 2010-07-15 Fritzinger David C Human complement c3 derivatives with cobra venom factor-like function

Also Published As

Publication number Publication date
JP2008502323A (ja) 2008-01-31
US8632780B2 (en) 2014-01-21
US20080311132A1 (en) 2008-12-18
WO2005107785A3 (en) 2005-12-15
EP1755658A2 (en) 2007-02-28
WO2005107785A2 (en) 2005-11-17
MXPA06012321A (es) 2007-04-19
US20080234191A1 (en) 2008-09-25
IL178905A0 (en) 2007-03-08
AU2005240096A1 (en) 2005-11-17
EP1755658A4 (en) 2008-11-05
KR20070036057A (ko) 2007-04-02

Similar Documents

Publication Publication Date Title
US20080234191A1 (en) Human complement C3 derivates with cobra venom factor-like function
EP1346034B1 (en) VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE
WO2003029401A2 (en) Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
US7084253B2 (en) Protease-activated receptor PAR4 (ZCHEMR2)
US20100179092A1 (en) Human complement c3 derivatives with cobra venom factor-like function
JP4855627B2 (ja) 医薬用途のためのトロンボモジュリン
JP2003313199A (ja) コラーゲン誘発血小板凝集抑制剤
Vogel et al. Cobra venom factor: the unique component of cobra venom that activates the complement system
RU2186110C2 (ru) Рекомбинантный белок asp-паллидипин, способ его производства и очистки, вектор, штамм, фармацевтическая композиция
Fritzinger et al. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion
JP2001515720A (ja) β−デフェンシン
WO2005121340A1 (ja) 新規ガレクチン８改変体タンパク質及びその用途
US20120122107A1 (en) Homeostatic multidomain protein, and uses for it
JPH08511157A (ja) Ｘａファクター阻害活性を有する新規ポリペプチド
CA2378485A1 (en) Proliferation differentiation factor
WO2007072012A1 (en) Novel members of the kazal family of serine protease inhibitors
US6835381B1 (en) Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor
CA3201986A1 (en) Adamts13 variant having increased escaping rate or activity against autoantibody
CN101014362A (zh) 具眼镜蛇毒因子样功能的人补体c3衍生物
JPH08510903A (ja) 蛭ヒルド・メディシナリスの組換えｘａ因子インヒビターの作製
US7122342B1 (en) Protease-activated receptor PAR4 (ZCHEMR2)
CN100425695C (zh) 新型人Rab GTP酶，其编码序列及用途
JP2002508170A (ja) 哺乳動物カルシトニン様ポリペプチド−１
US20050244868A1 (en) Ten-M3 polypeptides and polynucleotides and their methods of use
WO2001000664A2 (en) Secreted alpha-helical protein-36

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130731